Trontinemab Shows Promise for Treatment of Alzheimer Disease in New Data at CTAD
Trontinemab showed a 92% reduction in amyloid plaques, according to new data from the Brainshuttle AD trial. The drug showed an ability to lower amyloid levels and…
Trontinemab showed a 92% reduction in amyloid plaques, according to new data from the Brainshuttle AD trial. The drug showed an ability to lower amyloid levels and…